Screening for Addiction Risk in Chronic Opioid Therapy

描述（由研究者提供）：该I期申请旨在开发阿片类药物成瘾潜力筛选器（SOAP），这是一种用于考虑接受阿片类药物治疗的慢性疼痛患者的自我管理的简短筛选工具。SOAP将识别可能有成瘾风险的个人。目前没有用于此目的的有效程序。 一个严格的，方法学的方法将建立可靠性和预测有效性第一阶段开始测试开发过程。 概念图程序将整合疼痛和成瘾专家，提供者和患者的输入，以创建慢性疼痛患者成瘾的操作定义。 概念图也被用来生成项目，并对它们进行概念评估。 最初的经验可行性测试，使用横截面方法，将导致SOAP的测试版在第二阶段进行前瞻性验证和交叉验证。将特别注意确保措施的有效性与成瘾史的慢性疼痛患者。将计算临界评分的灵敏度和特异性，并检查成瘾的预测试概率。Endo Pharmaceuticals已承诺提供实质性III期支持。由此产生的措施应该是可靠的，有效的，并易于在实践中使用。

DESCRIPTION (provided by investigator): This Phase I application aims to develop the Screener for Opioid Addiction Potential (SOAP), a self-administered, brief screening tool for chronic pain patients considered for opioid therapy. The SOAP will identify individuals who may be at risk for addiction. No current, validated procedure exists for this purpose. A rigorous, methodological approach will establish reliability and predictive validity Phase I begins the test development process. Concept mapping procedures will integrate input from experts on pain and addiction, providers, and patients to create an operational definition of addiction in chronic pain patients. Concept mapping is also employed to generate items and subject them to a conceptual evaluation. An initial empirical feasibility test, using cross sectional methods, will result in a beta version of the SOAP to be prospectively validated and cross-validated in Phase II. Special attention will be paid to ensure validity of the measure for chronic pain patients with addiction histories. Sensitivity and specificity of cutoff scores will be calculated and examined with respect to pre-test probabilities of addiction Substantial Phase Ill support has been committed by Endo Pharmaceuticals. The resulting measure should be reliable, valid, and easy to use in practice settings.